Program Overview
This program is derived from content presented at the Consortium of Multiple Sclerosis Centers (CMSC) 34th Annual Meeting. This CME/CE activity will highlight advanced therapeutic strategies and family planning best practices for women with multiple sclerosis (MS). The expert faculty, led by Dr. Fred D. Lublin, will analyze the immunopathology, epidemiology, and immune therapeutic targets for MS. Recent clinical trial data and current therapies for the effective treatment of women with multiple sclerosis through their child-bearing years will be reviewed. The expert faculty will conclude with a review of the vital role that the interprofessional team plays in educating and caring for women of child-bearing age who have MS.
Target Audience
Healthcare professionals who care for patients with MS, including neurologists, primary care physicians, obstetricians/gynecologists, PAs, NPs, RNs, nurse educators and pharmacists
Agenda
I. Welcome and Introductions – Fred D. Lublin, MD
II. Immuno-pathology, Epidemiology, and Immune Therapeutic Targets for Multiple Sclerosis – Scott Douglas Newsome, DO
III. Current Practice and Clinical Trial Analysis for the Safe and Effective Treatment of Women with MS throughout the Child-bearing Years – Amy Perrin Ross, APN, MSN, CNRN, MSCN
IV. The Role of the Essential Interprofessional Team to Educate and Care for Women of Child-bearing Age who have MS – Kathleen Costello, MS, ANP-BC, MSCN
V. Interactive Panel Discussion – Fred D. Lublin, MD and Expert Faculty
Learning Objectives
- Explain the epidemiology, immunopathology, and immune therapeutic targets for MS
- Analyze current practice and clinical trial data for the safe and effective treatment of women with MS, and the implications for family planning, including preconception, pregnancy, and post-partum settings
- Optimize the interprofessional team to educate and provide care for women of child-bearing age who have MS
Faculty
Fred D. Lublin, MD (Course Chair)
Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, New York
Kathleen Costello, MS, ANP-BC, MSCN
Vice-President, Healthcare Access
National Multiple Sclerosis Society
John Hopkins Multiple Sclerosis Center
Baltimore, Maryland
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Neuroscience Program Coordinator
Loyola University Medical Center
Maywood, Illinois
Scott Douglas Newsome, DO
Director, Neurosciences Consultation and Infusion Center at Green Spring Station
Director, Stiff Person Syndrome Center
Co-Director, Multiple Sclerosis Experimental Therapeutics Program
Director, Optical Coherence Tomography Clinic
Associate Professor of Neurology
Johns Hopkins University School of Medicine
Baltimore, Maryland
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
| Faculty | Relationship Identified With: |
| Fred D. Lublin, MD (Course Chair) | Consultant/Advisor: Actelion Pharmaceuticals Ltd; Apitope; Atara Biotherapeutics, Inc.; Biogen; BrainStorm Cell Limited; Celgene Corporation: A Bristol-Myers Squibb Company; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GW Pharmaceuticals; Innate Immunotherapeutics; Jazz Pharmaceuticals; Orion Biotechnology Canada, Ltd.; Polpharma; Population Council; Receptos Inc.; Sanofi Genzyme; Teva Pharmaceutical Industries Ltd.; TG Theraputics
Grant/Research Support: Actelion Pharmaceuticals Ltd; Biogen; BrainStorm Cell Limited; Novartis; Sanofi Genzyme Speaker’s Bureau: Sanofi Genzyme |
| Kathleen Costello, MS, ANP-BC, MSCN | Nothing to disclose |
| Amy Perrin Ross, APN, MSN, CNRN, MSCN | Consultant/Advisor: Alexion Pharmaceuticals; Biogen; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Mallinckrodt Pharmaceuticals; Novartis; Sanofi Genzyme; Veil Bio
Speaker’s Bureau: Alexion Pharmaceuticals; Biogen; EMD Serono, Inc.; Genentech, Inc.; Mallinckrodt Pharmaceuticals; Novartis; Sanofi Genzyme |
| Scott Douglas Newsome, DO
|
Consultant/Advisor: Biogen; BioIncept, LLC.; EMD Serono, Inc.; Genentech, Inc.; MedDay Pharmaceuticals |
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Charles Pollack, MD, MA; Kim Cheramie, MSN, RN-BC; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM.
AcademicCME designates this enduring material for a maximum of 1.50 CNE Contact Hours, including 1.50 Pharmacotherapeutic Contact Hours (Provider number P0491).
AcademicCME designates this continuing education activity for 1.50 CPE Contact Hours (0.15s CEUs) of continuing pharmacy education credit (UAN # JA4008190-0000-20-002-H01-P).
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Medical Knowledge MOC Points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participation completion information to ACCME for the purpose of granting ABIM MOC credit.
Financial Support
This activity has been supported by an independent educational grant from EMD Serono, Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and EMD Serono, Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions.
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].
